Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Truist Financial

Equities research analysts at Truist Financial began coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The firm set a “buy” rating and a $21.00 price target on the stock. Truist Financial’s price target suggests a potential upside of 71.01% from the company’s previous close.

CATX has been the topic of several other research reports. Bank of America initiated coverage on Perspective Therapeutics in a report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price target on the stock. Royal Bank of Canada cut their target price on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Oppenheimer reduced their target price on shares of Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.00.

Perspective Therapeutics Stock Up 0.4 %

Perspective Therapeutics stock opened at $12.28 on Wednesday. Perspective Therapeutics has a 1 year low of $2.20 and a 1 year high of $19.05. The firm has a 50 day moving average of $13.80.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million for the quarter. On average, research analysts predict that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Several large investors have recently modified their holdings of CATX. Sykon Capital LLC grew its stake in shares of Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after purchasing an additional 1,717 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics during the second quarter worth $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics in the 2nd quarter valued at about $118,000. The Manufacturers Life Insurance Company acquired a new stake in Perspective Therapeutics during the 2nd quarter worth $188,000. Finally, ZWJ Investment Counsel Inc. bought a new stake in Perspective Therapeutics in the first quarter valued at about $26,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.